{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:14:13Z","timestamp":1783779253722,"version":"3.55.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Limited data from randomized controlled trials (RCTs) indicate that lorundrostat, an aldosterone synthase inhibitor, may be effective in managing uncontrolled hypertension (HTN). Currently, no systematic review or meta-analysis (SR\/MA) has assessed the safety and efficacy of the drug in such clinical conditions; this SR\/MA aims to fill that knowledge gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Electronic databases and registers were searched from inception to June 30, 2025, for RCTs involving lorundrostat in the intervention arm and placebo in the control arm in individuals with uncontrolled HTN. The primary outcome was lorundrostat safety; additional outcome was its efficacy in lowering blood pressure (BP). Meta-analyses were conducted using the RevMan web with random-effects models, presenting results as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Three low-bias RCTs with 1568 subjects were included. Over 6\u201312 weeks, lorundrostat (50 mg: RR 1.4 [1.23, 1.63]; 100 mg: RR 1.49 [1.29, 1.72]) increased risks of any adverse events (AEs), but not serious AEs, compared to placebo. Lorundrostat at both doses increased the risk of symptomatic hypotension. The lorundrostat group experienced a larger decrease in estimated glomerular filtration rate and an increase in serum potassium levels. Lorundrostat 50\u2009mg lowered office systolic (MD \u221211.11\u2009mm Hg) and diastolic BP (MD \u22123.87\u2009mm Hg) more than placebo, but not 24-hour ambulatory systolic BP. Lorundrostat 100\u2009mg lowered office systolic (MD \u22128.09\u2009mm Hg) and 24-hour ambulatory systolic BP (MD \u22127.18\u2009mm Hg) more than placebo, but did not affect office diastolic BP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Lorundrostat effectively manages uncontrolled HTN but increases the risk of some AEs. More RCTs involving diverse populations are needed to improve clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049158","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:00:19Z","timestamp":1780718419000},"page":"e49158","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"A.B.M.","family":"Kamrul-Hasan","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3555-4412","authenticated-orcid":false,"given":"Subhankar","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Medical College & Hospital, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-5554","authenticated-orcid":false,"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Nair","sequence":"additional","affiliation":[{"name":"Consultant Physician in Diabetes & Endocrinology, Clinical Service Lead, Countess of Chester Hospital NHS Foundation Trust, Chester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":false,"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, CEDAR Superspeciality Healthcare, Dwarka, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-5255","authenticated-orcid":false,"given":"Joseph M.","family":"Pappachan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston, UK"},{"name":"Faculty of Science, Manchester Metropolitan University, Manchester, UK"},{"name":"Department of Endocrinology, Kasturba Medical College and Manipal Academy of Higher Education, Manipal, Karnataka, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260711","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1573402115666191011111402","article-title":"Resistant hypertension: novel insights.","volume":"16","author":"Lamirault","year":"2020","journal-title":"Curr Hypertens Rev"},{"key":"R2-20260711","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCULATIONAHA.124.072415","article-title":"The journey of resistant hypertension: from the fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure to American Heart Association\/American College of Cardiology Guidelines.","volume":"151","author":"Vongpatanasin","year":"2025","journal-title":"Circulation"},{"key":"R3-20260711","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients.","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"R4-20260711","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension..","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"R5-20260711","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"R6-20260711","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MNH.0000000000001081","article-title":"Novel approaches in antihypertensive pharmacotherapeutics.","volume":"34","author":"Copur","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R7-20260711","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"R8-20260711","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1159\/000542621","article-title":"Aldosterone synthase inhibitors for cardiorenal protection: ready for prime time?","volume":"49","author":"Mazzieri","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"R9-20260711","doi-asserted-by":"crossref","first-page":"e70000","DOI":"10.1111\/cts.70000","article-title":"First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.","volume":"17","author":"Shimizu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"R10-20260711","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review.","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"R11-20260711","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R13-20260711","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1111\/cob.70008","article-title":"Metabolic outcomes of bariatric surgery versus lifestyle intervention in adolescents with severe obesity: a systematic review and meta-analysis.","volume":"15","author":"Kamrul-Hasan","year":"2025","journal-title":"Clin Obes"},{"key":"R15-20260711","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R16-20260711","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"R17-20260711","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R18-20260711","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension.","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"R19-20260711","first-page":"e259413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN Randomized Clinical Trial.","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"key":"R20-20260711","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN Randomized Clinical Trial.","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"R21-20260711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases.","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"key":"R22-20260711","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/ndt\/gfad101","article-title":"The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.","volume":"38","author":"Whitlock","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R23-20260711","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/qjmed\/hcg157","article-title":"Risk factors for thiazide-induced hyponatraemia.","volume":"96","author":"Chow","year":"2003","journal-title":"QJM"},{"key":"R24-20260711","first-page":"e36184","article-title":"Aldosterone synthase inhibitors and dietary interventions: a combined novel approach for prevention and treatment of cardiovascular disease.","volume":"15","author":"Awosika","year":"2023","journal-title":"Cureus"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:00:12Z","timestamp":1783778412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":22,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049158","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"2025-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}